Skip to content

Observation on the Efficacy of Mahuang Lianqiao Chixiaodou Tang Jiajian for the Treatment of Acute Eczema (Shi Re Jin Yin Syndrome)

The Efficacy of Mahuang Lianqiao Chixiaodou Decoction with Modifications in the Treatment of Acute Eczema (Damp-Heat Infiltration Syndrome)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002534
Enrollment
Unknown
Registered
2025-12-24
Start date
2025-11-27
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute eczema

Interventions

Control Group:Boric acid solution wet combined with oral administration of cetirizine hydrochloride tablets.
Observation group:In addition to the control group, Mahuang Lianqiao Chixiaodou Decoction was administered orally with modifications.

Sponsors

Shiyan City People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Concurrently meet the diagnostic criteria of Western medicine and the criteria of damp-heat syndrome in Traditional Chinese Medicine; (2) Age between 18 and 70 years, with no restriction on gender; (3) No history of receiving glucocorticoids, antihistamines, immunosuppressants, or traditional Chinese medicine related to the treatment of acute eczema within the past 2 weeks prior to enrollment; (4) Patients and their families are fully informed about the content of this study, voluntarily sign the informed consent form, and are able to cooperate to complete the treatment and follow-up.

Exclusion criteria

Exclusion criteria: (1) Patients with other skin diseases, such as seborrheic dermatitis, psoriasis, neurodermatitis, or malignant skin tumors, which may affect the assessment of treatment efficacy; (2) Patients with an eczema area and severity index score =23 points, classified as severe acute eczema; (3) Patients with dysfunction of major organs such as heart, liver, kidney, or brain, or with underlying conditions such as autoimmune diseases, hematological disorders, or active infections; (4) Pregnant or breastfeeding women; (5) Patients with a clear history of allergy to the drugs used in this study (boric acid solution, hydrochloride cetirizine tablets, and the components of the Ephedra Forsythia Red Bean Decoction); (6) Patients with mental disorders, consciousness disorders, or cognitive dysfunction, who are unable to cooperate with symptom assessment and treatment; (7) Patients currently participating in other clinical studies.

Design outcomes

Primary

MeasureTime frame
Clinical Efficacy;

Secondary

MeasureTime frame
Traditional Chinese Medicine Syndrome Score;eczema area and severity index Scoring;Visual Analog Scale;Proportion of nighttime itching duration.;inflammatory factor;Adverse Reaction;

Countries

China

Contacts

Public ContactYuan Duo

Shiyan People's Hospital

yuanduo1987@163.com13971930032

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026